Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 5/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553830 | 0.84 | L3MBTL1 (0.62) | KLKB1L3MBTL1POLBTDP1HSD17B10 | |
| SCHEMBL2819485 | 0.82 | KLKB1 (0.55) | KLKB1KMT2AMEN1 | |
| SCHEMBL554388 | 0.81 | KLKB1 (0.62) | KLKB1L3MBTL1POLBTDP1HSD17B10 | |
| SCHEMBL31352729 | 0.81 | HSD17B10 (0.56) | KLKB1L3MBTL1POLBTDP1HSD17B10 | |
| SCHEMBL1912400 | 0.81 | HSD17B10 (0.77) | KLKB1L3MBTL1POLBTDP1HSD17B10 | |
| SCHEMBL16247134 | 0.80 | ALKBH1 (0.60) | KLKB1L3MBTL1POLBTDP1HSD17B10 | |
| SCHEMBL1703634 | 0.80 | KMT2A (0.59) | KLKB1L3MBTL1HSP90AB1KMT2AMEN1 | |
| SCHEMBL19299982 | 0.79 | HSD17B10 (0.65) | KLKB1L3MBTL1POLBTDP1HSD17B10 | |
| SCHEMBL30755248 | 0.79 | HSD17B10 (0.57) | KLKB1L3MBTL1POLBTDP1HSD17B10 | |
| SCHEMBL3591944 | 0.79 | HSD17B10 (0.61) | L3MBTL1POLBTDP1HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-2601189-B1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| CN-103080104-B | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein | NOVARTIS AG | 2015-04-08 | — | — | CN | disclosed |
| US-20140378474-A1 | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | NOVARTIS AG (CH) | 2014-12-25 | — | — | US | disclosed |
| EP-2807157-A1 | 5-MEMBERED HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Novartis AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013111108-A1 | 5-MEMBERED HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | NOVARTIS AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| EP-2601189-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | Novartis AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| CN-103080104-A | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein | NOVARTIS AG | 2013-05-01 | — | — | CN | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017020-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378474-A1 | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885L3MBTL1 4120/4885POLB 4757/4885 |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | TPMT, REN, PNMT | KLKB1 4526/4885L3MBTL1 4829/4885POLB 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.